

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|---|----------------|
| Name of entity ZELIRA THERAPEUTICS LIMITED | |
| ABN | 27 103 782 378 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|------------------|
| Name of Director | Osagie Imasogie |
| Date of last notice | 24 November 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | |
| Date of change | 13 December 2024 |
| No. of securities held prior to change | A. 428,883 ordinary shares B. 335,094 Class B performance rights C. 30,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 30,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 30,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 30,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 30,000 - unlisted options expiring 24/11/2027 @ \$10.00 |
| Class | H. Convertible Notes |
| Number acquired | 3,500,000 |
| Number disposed | |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | USD1,400,000 |
| No. of securities held after change | A. 428,883 ordinary shares B. 335,094 Class B performance rights C. 30,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 30,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 30,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 30,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 30,000 - unlisted options expiring 24/11/2027 @ \$10.00 H. 3,500,000 Convertible Notes |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of Convertible notes to replace Convertible Loan Agreement approved by shareholders 14 November 2024. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A |
|---|-----|

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|-----|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.